The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

ConditionsCancer of Stomach Oesophageal Cancer Gastric Cancer Gastric Adenocarcinoma GI Cancer GIST Neuroendocrine Tumors Gastric Neoplasm Esophageal Neoplasms

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorWestern Sydney Local Health District

About this trial

To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions

Eligibility criteria

Qualifiers

UGI neoplastic lesions > 10mm

Lesions for ESD limited to the mucosal and/or submucosal layer OR

Lesions for EFTR limited to the muscularis propria layer OR

Lesions for STER limited to the submucosal and/or muscularis propria layer

Disqualifiers

Age less than 18

Unable to give informed consent

Pregnant or lactating patients

Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally

Trial design

Treatments tested in this trial

Not listed

Trial groups

500 Participants

are grouped into 1 trial group

Sponsors and collaborators

Western Sydney Local Health District

Lead sponsor

Source ClinicalTrials.gov